

## IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient has received an engineered autologous T-cell immunotherapy product that can lead to severe and even fatal cytokine release syndrome and neurologic adverse reactions. Cytokine release syndrome may involve any organ system.
- **WARNING:** Cytokine release syndrome and neurologic adverse reactions. See Summary of Product Characteristics for full details.

## IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (continued)

- Assess the patient for signs and symptoms of cytokine release syndrome and neurologic adverse reactions.
- See the Healthcare Provider Educational Material on how to manage cytokine release syndrome and neurologic adverse reactions.
- **Contact the patient's physician immediately for further information.**

## MY TREATING HEALTHCARE PROVIDER CONTACT INFORMATION & DATE OF INFUSION

Name of treating healthcare provider: \_\_\_\_\_

Office phone: \_\_\_\_\_

After-hours phone: \_\_\_\_\_

My name and phone: \_\_\_\_\_

Product infused: *Write name of product infused* \_\_\_\_\_

Product batch number: \_\_\_\_\_

Date of infusion: \_\_\_\_\_

## IMPORTANT REMINDERS FOR PATIENTS

- If you experience severe nausea, vomiting, diarrhoea, tiredness or any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare provider, or any healthcare provider available.
- Do not treat any of these symptoms with over-the-counter medications or herbal/dietary supplements without the approval of your treating healthcare provider.

## Patient Alert Card

Yescarta® ▼ (axicabtagene ciloleucel) Dispersion for infusion  
Tecartus® ▼ (autologous anti-CD19-transduced CD3+ cells)  
Dispersion for infusion

▼ These medicinal products are subject to additional monitoring. Take this card with you if you go to the hospital or see any doctor other than your treating healthcare provider.

**Be sure to tell all healthcare providers you see that you are being treated with an autologous T-cell immunotherapy and SHOW THEM THIS CARD.**

## IMPORTANT REMINDERS FOR PATIENTS (continued)

*Write name of product infused*

can cause serious side effects in different parts of your body. These symptoms can be life-threatening or even fatal and need to be addressed immediately.

**Symptoms that appear mild may quickly worsen.**

**Symptoms may be delayed and may occur weeks after your infusion.**

**Do not feel embarrassed or that you are inconveniencing your healthcare provider.**

## Call your treating healthcare provider right away if you have any of these symptoms

### Neurologic Adverse Reactions

- Confusion
- Difficulty speaking
- Difficulty understanding speech
- Tremors (shaky arms or body parts)
- Agitation
- Increased sleepiness
- Dizziness

### Cytokine Release Syndrome

- Fever (eg, temperature above 38°C)
- Tiredness
- Shortness of breath
- Low urine output
- Nausea
- Vomiting
- Diarrhoea
- Irregular heartbeat

## REPORTING OF SIDE EFFECTS

- If you get side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the patient information leaflet. You can also report side effects directly via the national reporting system:

Yellow Card Scheme

Website: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)

MHRA Yellow Card in the Google Play or Apple App Store

Tel: **+44 (0) 800 731 6789**

Any suspected adverse reactions to axicabtagene ciloleucel or autologous anti-CD19-transduced CD3+ cells should be reported to Gilead via email to [Safety\\_FC@gilead.com](mailto:Safety_FC@gilead.com) or by telephone **+44 (0) 1223 897500**.

Please see the axicabtagene ciloleucel or autologous anti-CD19-transduced CD3+ cells Summary of Product Characteristics, including the Patient Information Leaflet and the Healthcare Provider Educational Material, all of which can be obtained by contacting Kite, a Gilead Company, Medical Information at [ukmedinfo@gilead.com](mailto:ukmedinfo@gilead.com) or by telephone on **+44 (0) 8000 113700**.

The European Society for Blood and Marrow Transplantation (EBMT) is maintaining a registry for follow up of patients who received axicabtagene ciloleucel or autologous anti-CD19-transduced CD3+ cells. Additional information can be obtained from: [registryhelpdesk@ebmt.org](mailto:registryhelpdesk@ebmt.org).

Yescarta, the Yescarta Logo, Tecartus, the Tecartus logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.  
© 2020 Kite Pharma, Inc.  
UK-CTH-2020-11-0004 Date of preparation: January 2021

